Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.
|Webcasts|September 27, 2020
Layer by Layer: The Fundamentals of Multi-Layer Tableting
Author(s)JRS PHARMA
***Live: Tuesday, Oct. 27, 2020 *** Multi-layer tableting offers an inexpensive and straightforward solution for a variety of challenging formulations. Learn how multi-layer formulations compare to traditional methods, gain insight to the multi-layer tableting process, and crucial tips to formulating and manufacturing robust multi-layer tablets. ***On demand available after final airing until Oct. 27, 2021***
Register free:
Event Overview:
Multi-layer tableting offers an inexpensive and straightforward solution for a variety of challenging formulations. Enabling multi-phasic release systems, combinations of incompatible APIs, and gastro-retentive tablets, this under-utilized method provides efficiency and cost-savings compared to more popular complex processes.
This webcast will compare multi-layer formulation options to traditional methods, providing a step-by-step guide to the multi-layer tableting process, and offering crucial tips to formulating and manufacturing robust multi-layer tablets. Learn how tooling considerations, excipient selection, layer design, and tamping force adjustment can impact overall tablet robustness, as well as layer-to-layer adhesion.
Key Learning Objectives:
- Understand the basics of multi-layer tablet formulations and its drug delivery possibilities.
- Follow step-by-step through the multi-layer tableting process.
- Learn essential tips for creating robust multi-layer tablets, from tooling considerations, excipient selection, layer design, to tamping force adjustment.
Speaker: Anthony Carpanzano, Director of R&D, JRS PHARMA
Time and Date: Tuesday, Oct. 27, 2020 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST
On demand available after final airing until Oct. 27, 2021
Sponsor: JRS PHARMA
Register free:
Related to this article
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
Our Biggest Takeaways From AAPS PharmSci 360
3
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
4
PharmTech AI Pulse Check: Who's Accountable When a Vendor's AI Model Changes?
5